Document is current
Any future updates will be listed below
-
Authors
Sudharsan, Raghavi http://orcid.org/0000-0001-7839-5178
Kwok, Jennifer http://orcid.org/0000-0002-1995-0095
Swider, Malgorzata
Sumaroka, Alexander
Aguirre, Gustavo D.
Cideciyan, Artur V.
Beltran, William A. http://orcid.org/0000-0002-1127-4774
-
Funding
Funding for this research was provided by:
Foundation Fighting Blindness (NA, NA)
McCabe Fund Pilot Grant University Research Foundation, University of Pennsylvania
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY006855, EY006855, EY017549)
S.G.Jacobson MD PhD Memorial Fund Unrestricted funds from RPB
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
- License Information
-
More Information
Article History
Received: 20 December 2023
Revised: 3 September 2024
Accepted: 12 September 2024
First Online: 18 September 2024
Competing interests
: RS and WAB have a provisional patent filed by the University of Pennsylvania on “Modulation of <i>PRLΔE1</i> expression for the treatment of inherited retinal degenerations” The other authors declare no competing financial interests.
: All methods were performed in accordance with the relevant guidelines and regulations. The animal studies adhered to the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.
